Literature DB >> 14565688

The effects of one-week fluticasone propionate inhalation therapy for Tc-99m DTPA radioaerosol distribution in asthma of children: a preliminary report.

A C Chen1, F J Tsai, J J P Tsai, C C Lin, C C Lee, A Kao.   

Abstract

This study evaluated the effects of fluticasone propionate inhalation therapy for the distribution pattern of Tc-99m DTPA radioaerosols in 10 children with asthma. The homogeneous degree of depositing Tc-99m DTPA radioaerosol was evaluated using a modified standard score system over the bilateral lungs. The baseline scores were calculated from Tc-99m DTPA radioaerosol inhalation lung scintigraphy before inhalation therapy (100 microg fluticasone propionate two times daily for one week), and the scores were recalculated after inhalation therapy to evaluate the effects of one-week of fluticasone propionate inhalation therapy for Tc-99m DTPA radioaerosol distribution patterns. After one week of fluticasone propionate inhalation therapy, the scores were decreased in all of the 10 children, which may mean that the bronchial constriction degree due to asthma is decreased. In addition, there was a significantly statistical difference in the scores before and after one-week fluticasone propionate inhalation therapy (p < 0.05). In conclusion, one-week fluticasone propionate inhalation therapy could significantly improve the bronchial constriction due to asthma in children based on the evidence of Tc-99m DTPA radioaerosol inhalation lung scintigraphic findings.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14565688     DOI: 10.1007/s00408-003-1016-z

Source DB:  PubMed          Journal:  Lung        ISSN: 0341-2040            Impact factor:   2.584


  10 in total

1.  DISTRIBUTION OF PULMONARY VENTILATION DETERMINED BY RADIOISOTOPE SCANNING. A PRELIMINARY REPORT.

Authors:  F J PIRCHER; J R TEMPLE; W J KIRSCH; R J REEVES
Journal:  Am J Roentgenol Radium Ther Nucl Med       Date:  1965-08

2.  Efficacy and safety of dry powder fluticasone propionate in children with persistent asthma.

Authors:  C F LaForce; D S Pearlman; M E Ruff; W S Silvers; S W Weinstein; D S Clements; A Brown; S Duke; S M Harding; K W House
Journal:  Ann Allergy Asthma Immunol       Date:  2000-11       Impact factor: 6.347

3.  Evaluation of lung ventilation and alveolar permeability in cirrhosis.

Authors:  C H Kao; C K Huang; S C Tsai; S J Wang; G H Chen
Journal:  J Nucl Med       Date:  1996-03       Impact factor: 10.057

4.  Pathogenesis of asthma.

Authors:  E R McFadden
Journal:  J Allergy Clin Immunol       Date:  1984-04       Impact factor: 10.793

5.  Airway inflammation in mild intermittent and in persistent asthma.

Authors:  A M Vignola; P Chanez; A M Campbell; F Souques; B Lebel; I Enander; J Bousquet
Journal:  Am J Respir Crit Care Med       Date:  1998-02       Impact factor: 21.405

6.  Effects of long-term treatment with an inhaled corticosteroid on growth and pulmonary function in asthmatic children.

Authors:  L Agertoft; S Pedersen
Journal:  Respir Med       Date:  1994-05       Impact factor: 3.415

7.  The change in the distribution of Tc-99m human serum albumin radioaerosols in asthma after a 1-week course of corticosteroid inhalation treatment.

Authors:  S P Changlai; C H Kao; S J Wang; W Y Lin; J L Lan
Journal:  Clin Nucl Med       Date:  1995-07       Impact factor: 7.794

8.  Damage of the airway epithelium and bronchial reactivity in patients with asthma.

Authors:  L A Laitinen; M Heino; A Laitinen; T Kava; T Haahtela
Journal:  Am Rev Respir Dis       Date:  1985-04

9.  Fluticasone propionate 50 micrograms BID versus 100 micrograms BID in the treatment of children with persistent asthma. Fluticasone Propionate Study Group.

Authors:  Y Katz; F X Lebas; H V Medley; R Robson
Journal:  Clin Ther       Date:  1998 May-Jun       Impact factor: 3.393

Review 10.  Fluticasone propionate--an update on preclinical and clinical experience.

Authors:  R Fuller; M Johnson; A Bye
Journal:  Respir Med       Date:  1995-09       Impact factor: 3.415

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.